STK11 - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
APP	amyloid beta precursor protein	Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1 activates NFkB by phosphorylation and activation of IKKs complex The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form	Alzheimer's disease (AD)
CDK4	cyclin dependent kinase 4	SCF(Skp2)-mediated degradation of p27/p21 Oxidative Stress Induced Senescence Senescence-Associated Secretory Phenotype (SASP) Oncogene Induced Senescence RMTs methylate histone arginines Transcriptional regulation of white adipocyte differentiation Cyclin D associated events in G1 Ubiquitin-dependent degradation of Cyclin D Ubiquitin-dependent degradation of Cyclin D PTK6 Regulates Cell Cycle Transcriptional regulation by RUNX2 Meiotic recombination Transcriptional regulation of granulopoiesis Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	Purvalanol Alvocidib Palbociclib Ribociclib Abemaciclib Fostamatinib	Glioma Malignant melanoma Cervical cancer
MET	MET proto-oncogene, receptor tyrosine kinase	PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D mediated inhibition of cell attachment and migration RAF/MAP kinase cascade MET Receptor Activation Negative regulation of MET activity PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates RAS signaling MET activates PI3K/AKT signaling MET activates PTPN11 MET activates PTK2 signaling InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell MET interacts with TNS proteins MET activates RAP1 and RAC1 MET receptor recycling MET activates STAT3 MECP2 regulates neuronal receptors and channels	K-252a SGX-523 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol AMG-208 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE Crizotinib Cabozantinib Capmatinib Fostamatinib Tivantinib Brigatinib Amuvatinib	Renal cell carcinoma Cholangiocarcinoma Gastric cancer
HGF	hepatocyte growth factor	Platelet degranulation PIP3 activates AKT signaling Interleukin-7 signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling MET Receptor Activation Negative regulation of MET activity PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates RAS signaling MET activates PI3K/AKT signaling MET activates PTPN11 MET activates PTK2 signaling MET interacts with TNS proteins MET activates RAP1 and RAC1 MET receptor recycling MET activates STAT3	Heparin O2-Sulfo-Glucuronic Acid N,O6-Disulfo-Glucosamine ABT-510 Foretinib
KAT2A	lysine acetyltransferase 2A	Pre-NOTCH Transcription and Translation Pre-NOTCH Transcription and Translation Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells NOTCH1 Intracellular Domain Regulates Transcription NOTCH1 Intracellular Domain Regulates Transcription Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants HATs acetylate histones Notch-HLH transcription pathway B-WICH complex positively regulates rRNA expression Ub-specific processing proteases RNA Polymerase I Transcription Initiation RUNX3 regulates NOTCH signaling RUNX3 regulates NOTCH signaling NOTCH3 Intracellular Domain Regulates Transcription NOTCH3 Intracellular Domain Regulates Transcription NOTCH4 Intracellular Domain Regulates Transcription	Coenzyme A
BRAF	B-Raf proto-oncogene, serine/threonine kinase	Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by MRAS-complex mutants	Sorafenib XL281 RAF-265 PLX-4720 N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib Encorafenib Fostamatinib Ripretinib	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer Malignant melanoma
MAP2K1	mitogen-activated protein kinase kinase 1	MAPK3 (ERK1) activation Frs2-mediated activation Signal transduction by L1 Uptake and function of anthrax toxins RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway MAP3K8 (TPL2)-dependent MAPK1/3 activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by MAP2K mutants Signaling by RAF1 mutants	K-252a 5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide Cobimetinib Bosutinib (5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide 2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide PD-0325901 N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine 2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE Trametinib Selumetinib	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
MYC	MYC proto-oncogene, bHLH transcription factor	Transcription of E2F targets under negative control by DREAM complex NOTCH1 Intracellular Domain Regulates Transcription SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Constitutive Signaling by NOTCH1 PEST Domain Mutants Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Binding of TCF/LEF:CTNNB1 to target gene promoters MAPK6/MAPK4 signaling Ub-specific processing proteases Interleukin-4 and Interleukin-13 signaling Cyclin E associated events during G1/S transition Cyclin A:Cdk2-associated events at S phase entry TFAP2 (AP-2) family regulates transcription of cell cycle factors RUNX3 regulates WNT signaling Estrogen-dependent gene expression Transcriptional regulation of granulopoiesis	Acetylsalicylic acid Nadroparin	Choriocarcinoma Penile cancer Burkitt lymphoma Oral cancer Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia) Multiple myeloma Small cell lung cancer Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia) Osteosarcoma Kaposi's sarcoma Laryngeal cancer Breast cancer Ovarian cancer
CCNE1	cyclin E1	G0 and Early G1 SCF(Skp2)-mediated degradation of p27/p21 DNA Damage/Telomere Stress Induced Senescence Association of TriC/CCT with target proteins during biosynthesis TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest CDK-mediated phosphorylation and removal of Cdc6 Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes Cyclin E associated events during G1/S transition G1/S-Specific Transcription Cyclin D associated events in G1 p53-Dependent G1 DNA Damage Response PTK6 Regulates Cell Cycle Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) RHOBTB3 ATPase cycle		Laryngeal cancer Gastric cancer
FGFR4	fibroblast growth factor receptor 4	PI3K Cascade PIP3 activates AKT signaling betaKlotho-mediated ligand binding FGFR4 mutant receptor activation FGFR4 ligand binding and activation Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade; FGFR4 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR4 signaling Signaling by FGFR4 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Heparin Ponatinib Lenvatinib Erdafitinib Pemigatinib
MAPRE1	microtubule associated protein RP/EB family member 1	Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion Regulation of PLK1 Activity at G2/M Transition Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Anchoring of the basal body to the plasma membrane RHO GTPases Activate Formins Mitotic Prometaphase The role of GTSE1 in G2/M progression after G2 checkpoint AURKA Activation by TPX2 EML4 and NUDC in mitotic spindle formation
MDM2	MDM2 proto-oncogene	AKT phosphorylates targets in the cytosol Oxidative Stress Induced Senescence Oncogene Induced Senescence SUMOylation of transcription factors SUMOylation of ubiquitinylation proteins Trafficking of AMPA receptors Constitutive Signaling by AKT1 E17K in Cancer Ub-specific processing proteases Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Methylation Stabilization of p53 Regulation of RUNX3 expression and activity	Zinc Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone Zinc acetate Zinc chloride Zinc sulfate, unspecified form	Choriocarcinoma Osteosarcoma Glioma Penile cancer Alveolar rhabdomyosarcoma
PDGFRA	platelet derived growth factor receptor alpha	PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Imatinib-resistant PDGFR mutants Sunitinib-resistant PDGFR mutants Regorafenib-resistant PDGFR mutants Sorafenib-resistant PDGFR mutants PDGFR mutants bind TKIs	Becaplermin Imatinib Sunitinib XL820 Olaratumab Pazopanib Midostaurin Regorafenib Ponatinib Lenvatinib Nintedanib Foreskin keratinocyte (neonatal) Fostamatinib Erdafitinib Amuvatinib Ripretinib	Glioma
YWHAG	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma	Activation of BAD and translocation to mitochondria Translocation of SLC2A4 (GLUT4) to the plasma membrane Regulation of PLK1 Activity at G2/M Transition Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Anchoring of the basal body to the plasma membrane RHO GTPases activate PKNs TP53 Regulates Metabolic Genes Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex AURKA Activation by TPX2 Regulation of localization of FOXO transcription factors
FZR1	fizzy and cell division cycle 20 related 1	Autodegradation of Cdh1 by Cdh1:APC/C SCF-beta-TrCP mediated degradation of Emi1 APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase Regulation of APC/C activators between G1/S and early anaphase Phosphorylation of Emi1 Senescence-Associated Secretory Phenotype (SASP) CDK-mediated phosphorylation and removal of Cdc6 Cyclin A:Cdk2-associated events at S phase entry Transcriptional Regulation by VENTX Aberrant regulation of mitotic exit in cancer due to RB1 defects Antigen processing: Ubiquitination & Proteasome degradation
PTEN	phosphatase and tensin homolog	Synthesis of PIPs at the plasma membrane Synthesis of IP3 and IP4 in the cytosol Negative regulation of the PI3K/AKT network Downstream TCR signaling TP53 Regulates Metabolic Genes PTEN Loss of Function in Cancer Ub-specific processing proteases Ovarian tumor domain proteases Regulation of PTEN mRNA translation Regulation of PTEN localization Regulation of PTEN stability and activity Transcriptional Regulation by MECP2	Phosphatidylethanolamine	Vulvar cancer Prostate cancer Endometrial Cancer Glioma Small cell lung cancer Breast cancer Hepatocellular carcinoma Malignant melanoma
TRIM25	tripartite motif containing 25	ISG15 antiviral mechanism DDX58/IFIH1-mediated induction of interferon-alpha/beta Termination of translesion DNA synthesis Ovarian tumor domain proteases Interferon gamma signaling TRAF3-dependent IRF activation pathway TRAF6 mediated IRF7 activation TRAF6 mediated NF-kB activation TRAF6 mediated NF-kB activation NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 Negative regulators of DDX58/IFIH1 signaling Negative regulators of DDX58/IFIH1 signaling
UBE2D2	ubiquitin conjugating enzyme E2 D2	Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha TICAM1, RIP1-mediated IKK complex recruitment Downstream TCR signaling FCERI mediated NF-kB activation CLEC7A (Dectin-1) signaling Synthesis of active ubiquitin: roles of E1 and E2 enzymes E3 ubiquitin ligases ubiquitinate target proteins Neddylation Peroxisomal protein import Negative regulators of DDX58/IFIH1 signaling IKK complex recruitment mediated by RIP1 Antigen processing: Ubiquitination & Proteasome degradation	(R,R)-2,3-Butanediol
LEF1	lymphoid enhancer binding factor 1	Formation of the beta-catenin:TCF transactivating complex Formation of the beta-catenin:TCF transactivating complex Deactivation of the beta-catenin transactivating complex Ca2+ pathway Binding of TCF/LEF:CTNNB1 to target gene promoters Repression of WNT target genes Repression of WNT target genes Transcriptional Regulation by VENTX RUNX3 regulates WNT signaling Transcriptional regulation of granulopoiesis Transcriptional regulation of granulopoiesis	Etacrynic acid
PRKAA2	protein kinase AMP-activated catalytic subunit alpha 2	Translocation of SLC2A4 (GLUT4) to the plasma membrane Macroautophagy AMPK inhibits chREBP transcriptional activation activity AMPK inhibits chREBP transcriptional activation activity Carnitine metabolism Activation of PPARGC1A (PGC-1alpha) by phosphorylation Energy dependent regulation of mTOR by LKB1-AMPK TP53 Regulates Metabolic Genes Regulation of TP53 Activity through Phosphorylation Lipophagy Activation of AMPK downstream of NMDARs	Adenosine phosphate Acetylsalicylic acid Fostamatinib

Search Results for: STK11